[PDF][PDF] Immunotherapy for type 1 diabetes: why do current protocols not halt the underlying disease process?
H Kolb, M von Herrath - Cell metabolism, 2017 - cell.com
H Kolb, M von Herrath
Cell metabolism, 2017•cell.comT cell-directed immunosuppression only transiently delays the loss of β cell function in
recent-onset type 1 diabetes. We argue here that the underlying disease process is carried
by innate immune reactivity. Inducing a non-polarized functional state of local innate
immunity will support regulatory T cell development and β cell proliferation.
recent-onset type 1 diabetes. We argue here that the underlying disease process is carried
by innate immune reactivity. Inducing a non-polarized functional state of local innate
immunity will support regulatory T cell development and β cell proliferation.
T cell-directed immunosuppression only transiently delays the loss of β cell function in recent-onset type 1 diabetes. We argue here that the underlying disease process is carried by innate immune reactivity. Inducing a non-polarized functional state of local innate immunity will support regulatory T cell development and β cell proliferation.
cell.com